Audit of clinical management of von Willebrand disease during 1997 at a single institution and review of treatment patterns between 1980 and 1997

Haemophilia

Volumn 5, Issue 5, 1999, Pages 327-333

  Nitu Whalley, I C ^a   Miners, A H ^a   Lee, C A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Audit; Clotting factor concentrates; Desmopressin; Guidelines; Treatment; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CRYOPRECIPITATE; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTORS; DEAMINO ARGININE VASOPRESSIN; GREAT BRITAIN; HUMANS; MEDICAL AUDIT; PRACTICE GUIDELINES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0032698831     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00341.x     Document Type: Article

References (24)

1. Sadler JE. Von Willebrand disease. In: Thrombosis and Haemostasis (eds A. Bloom & D. P. Thomas). London: Churchill Livingstone, 1993: 843-57.
2. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71 (4): 520-5.
3. Perkins HA. Correction of the haemostatic defects in von Willebrand's disease. Blood 1967; 30: 375.
4. Bennett E, Dormandy KM, Churchill WGL, Coward AR, Smith M, Cleghorn TE. Cryoprecipitate and the plastic blood-bag system: provision of adequate replacement therapy for routine treatment of haemophilia. BMJ 1967; 2: 88-91.
5. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. DDAVP: a new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1977; 1: 869.
6. Mannucci PM. Treatment of von Willebrand disease. Haemophilia 1998; 4: 661-4.
7. Anon. Guidelines for the diagnosis and management of von Willebrand disease. Haemophilia 1997; 3 (2): 4-8.
8. Mannucci PM. Desmopressin: a non-transfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-55.
9. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-9.
10. Berntrop E, Nilsson IM. Use of high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang 1989; 56: 21-7.
11. Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75: 228-33.
12. Cumming AM, Fildes S, Cumming IR et al. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease. Br J Haematol 1990; 75: 234-9.
13. Metzner HJ, Hermentin P, Cuesta-Linker T, Langer S, Muller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4 (3): 25-32.
14. Mannucci PM, Schimp K, Abe T et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Int Invest Group Transfusion 1992; 32: 134-8.
15. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-9.
16. Anon. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. United Kingdom Haemophilia Centre Directors Organisation Executive Committee. Haemophilia 1997; 3: 63-77.
17. Alusi GH, Grant WE, Lee CA, Pasi KJ, Sterns MP. Bleeding after tonsillectomy in severe von Willebrand's disease. J Laryngol Otol 1995; 109: 437-9.
18. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorn E. Platelet aggregation induced by 1deamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med 1983; 398: 816-21.
19. Mckeown LP, Connaghan G, Wilson O, Hansman K, Merryman P, Gralnick HR. 1-Desamino-8-Arginine - vasopressin corrects the haemostatic defects in type 2B von Willebrand's disease. Am J Haematol 1996; 51: 158-63.
20. Chediak JR, Alban GM, Maxey B. Von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am J Obstet Gynecol 1986; 155: 618-24.
21. UK Regional Hamophilia Centre Directors' Committee. Recommendations on choice of therapeutic products for the treatment of patients with haemophlia A, haemophilia B and von Willebrand's disease. Blood Coagul Fibrinolysis 1992; 3: 205-14.
22. Miners AH, Sabin CA, Tolley KH, Lee CA. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. Haemophilia 1998; 4: 4-9.
23. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90 (7): 2515-21.
24. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Int Med 1998; 244: 515-22.